Effects of Distance From Academic Cancer Center on Overall Survival of Acute Myeloid Leukemia: Retrospective Analysis of Treated Patients

Publication date: October 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 10Author(s): Prajwal Dhakal, Elizabeth Lyden, Kate-Lynn E. Muir, Zaid S. Al-Kadhimi, Lori J. Maness, Krishna Gundabolu, Vijaya Raj Bhatt
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

esco Albano Immunomodulatory drugs (IMiDs) are analogs of thalidomide. They have immunomodulatory, antiangiogenic and proapoptotic properties and exert a role in regulating the tumor microenvironment. Recently IMiDs have been investigated for their pleiotropic properties and their therapeutic applications in both solid tumors (melanoma, prostate carcinoma and differentiated thyroid cancer) and hematological malignancies. Nowadays, they are applied in de novo and relapsed/refractory multiple myeloma, in myelodysplastic syndrome, in del5q syndrome with specific use of lenalidomide and B-cell lymphoma. Several studies hav...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
CONCLUSIONS: There was no convincing evidence of an increased risk in any hematological malignancy when interpreting the results from both series of analyses. PMID: 32818321 [PubMed - as supplied by publisher]
Source: Transfusion - Category: Hematology Authors: Tags: Transfusion Source Type: research
We hypothesized that higher Charlson comorbidity index(CCI) predicts worse one-month mortality and overall survival(OS) in patients ≥60 years with acute myeloid leukemia(AML). In our National Cancer Database study, patients with CCI 0 were more likely to receive chemotherapy and undergo upfront hematopoietic cell transplant. One-month mortality and OS were significantly worse with CCI 1 or ≥2, compared to CCI 0.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
We examined the outcomes of 818 adult patients with relapsed/refractory acute myeloid leukemia (R/R AML) treated at MD Anderson Cancer Center between 2002 –2016. Complete remission rates decreased from 14% after first salvage, to 9% after second salvage, and 3% after third salvage. Strategies that improve initial response and decrease the likelihood of relapse are needed to achieve long-term remission for AML.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Publication date: Available online 21 April 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Samah Fathy Semary, Mahmoud Hammad, Sonya Soliman, Dina Yassen, Marwa Gamal, Doaa Albeltagy, Nayera Hamdy, Sonia Mahmoud
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 26 May 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Prajwal Dhakal, Elizabeth Lyden, E Muir Kate-Lynn, Zaid S. Al-Kadhimi, Lori J. Maness, Krishna Gundabolu, Vijaya Raj Bhatt
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study did not demonstrate an association between distance from an academic cancer center and OS in AML.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
This study did not demonstrate an association between distance from an academic cancer center and OS in AML.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Publication date: Available online 21 April 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Samah Semary, Mahmoud Hammad, Sonya Soliman, Dina Yassen, Marwa Gamal, Doaa Albeltagy, Nayera Hamdy, Sonia Mahmoud
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
In an analysis of the outcome of pediatric acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutation over 10 years at Children ’s Cancer Hospital Egypt, we found that FLT3-ITD mutation was associated with poor outcomes, and survival of patients who experienced relapse was extremely poor. Allogeneic bone marrow transplantation while the patient is experiencing first remission was the best treatment option. FLT3 inhibitors are needed to improve the outcome in AML in developing countries.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
More News: Academia | Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Leukemia | Lymphoma | Myeloma